Retrospective analysis of the effect of aflibercept loading dose on the retinal vessel diameters in patients with treatment-naive neovascular AMD


TETİKOĞLU M., KURT M. M., SAĞDIK H. M., AKTAŞ S., YILDIRIM M. A., ÖZCURA F.

CUTANEOUS AND OCULAR TOXICOLOGY, vol.37, no.1, pp.84-89, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.1080/15569527.2017.1354217
  • Journal Name: CUTANEOUS AND OCULAR TOXICOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.84-89
  • Keywords: Aflibercept, retinal vessel diameter, choroidal thickness, retinal blood flow, macular degeneration, ENDOTHELIAL GROWTH-FACTOR, BEAVER DAM EYE, VEGF TRAP-EYE, MACULAR DEGENERATION, INTRAVITREAL INJECTION, BLOOD-FLOW, CHOROIDAL THICKNESS, VISUAL IMPAIRMENT, RANIBIZUMAB, BEVACIZUMAB
  • Kütahya Health Sciences University Affiliated: No

Abstract

Background: To evaluate the effects of intravitreal aflibercept (IVA) on retinal vessel diameters in patients with neovascular age-related macular degeneration (AMD).Design, setting, and participants: A retrospective study conducted at the Kutahya Dumlupinar University Faculty of Medicine included 15 eyes of 15 patients with treatment naive neovascular AMD.Methods: All eyes received IVA injections once per month for 3months; untreated contralateral eyes were used as controls. The central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and artery-vein ratio (AVR) values were measured using a computer-based program before the first IVA injection and 30days after the first, second, and third injections. The main outcome measurements were the central macular thickness (CMT), best-corrected visual acuity (BCVA), choroidal thickness, CRAE, CRVE, and AVR.Results: Significant vasoconstriction of the retinal arterioles was observed in all eyes treated with IVA when compared to baseline (p=0.009). However, no significant differences were found for CRVE or AVR throughout the study period in treated eyes. In the control group, all parameters measured during each visit were similar to baseline measurements (p>0.05). The mean BCVA significantly improved at the end of the loading dose of IVA, when compared to baseline (p=0.006). After the IVA injections, the mean CMT and choroidal thickness were significantly reduced at all visits, compared to baseline (p<0.001).Conclusions: The current study showed that IVA led to significant retinal arteriolar vasoconstriction and choroidal thinning, which may cause reduced retinal blood flow.